Your browser doesn't support javascript.
loading
[Efficacy of Huang'e Capsules on benign prostatic hyperplasia with Qi-deficiency, blood stasis and damp heat block: A stratified analysis].
Jiang, Shao-Bo; Xu, Zhi-Hui; Jia, Jin-Ming.
Afiliação
  • Jiang SB; Department of Urology, The First Hospital Affiliated to Zhejiang University of Chinese Medicine, Hangzhou, Zhejiang 310006, China.
  • Xu ZH; Department of Urology, The First Hospital Affiliated to Zhejiang University of Chinese Medicine, Hangzhou, Zhejiang 310006, China.
  • Jia JM; Department of Andrology, Guanganmen Hospital of the China Academy of Chinese Medical Sciences, Beijing 100053, China.
Zhonghua Nan Ke Xue ; 24(9): 819-823, 2018 Sep.
Article em Zh | MEDLINE | ID: mdl-32212461
OBJECTIVE: To evaluate the efficacy and safety of Huang'e Capsules in the treatment of BPH with Qi-deficiency, blood stasis and damp heat block. METHODS: This study included 1 456 cases of BPH with Qi-deficiency, blood stasis and damp heat block from 40 hospitals of Zhejiang and Anhui Provinces between June 2014 and July 2017. The patients were aged 40-85 years and treated with Huang'e Capsules at a dose of 4 capsules, tid, for a course of 6 weeks. The IPSSs of the patients were obtained before and after 2, 4 and 6 weeks of medication, and a stratified analysis was made on the factors influencing the therapeutic effects, such as age, the stage of BPH, and concomitant medication of urogenital and reproductive hormone drugs. RESULTS: After 6 weeks of medication, the IPSS of the patients was decreased by 8.4 ± 5.4 (ï¼»42.9 ± 22.7ï¼½ %) as compared with the baseline (19.2 ± 6.8) (P < 0.05), with a total effectiveness rate of 71.9% and an excellence rate of 23.1%. After 6 weeks of medication, the IPSSs of the patients with stage-Ⅰ, -Ⅱ and -Ⅲ BPH were decreased by 7.3 ± 6.8, 6.6 ± 4.3 and 11.0 ± 5.5, with total effective rates of 69.5%, 70.1% and 74.7%, respectively, with statistically significant differences among the three stages (P < 0.05), and so were those in the patients aged ≤50 years (by 7.4 ± 5.8), 51-60 years (by 7.9 ± 5.3), 61-70 years (by 8.7 ± 5.6) and >70 years (by 8.6 ± 5.1), but with no statistically significant differences among different age groups (P > 0.05). At 6 weeks, the IPSS was reduced by 7.1 ± 5.9 by concomitant medication of urogenital and reproductive hormone drugs, 8.7 ± 5.4 by concomitant medication of other drugs, and 8.4 ± 5.3 by non-concomitant medication, with no statistically significant differences among the three types of medication (P > 0.05). CONCLUSIONS: Huang'e Capsules can evidently improve the symptoms of BPH, with the best effect on stage-Ⅲ BPH, and the effect does not differ significantly with age or drug concomitance.
Palavras-chave
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Idioma: Zh Ano de publicação: 2018 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Idioma: Zh Ano de publicação: 2018 Tipo de documento: Article